OverviewSuggest Edit

Hoth Therapeutics is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Company also develops the BioLexa Platform, a product candidate intended to prevent the symptom-triggering flare-ups before they occur.

TypePublic
HQNew York, NY, US
Websitehoththerapeutics.com

Latest Updates

Employees (est.) (Feb 2020)2
Share Price (May 2021)$1.4(+4%)
Cybersecurity ratingBMore

Hoth Therapeutics Office Locations

Hoth Therapeutics has an office in New York
New York, NY, US (HQ)
1 Rockefeller Plaza, 10th Floor
Show all (1)

Hoth Therapeutics Financials and Metrics

Hoth Therapeutics Revenue

USD

Net income (Q1, 2021)

(4.3m)

EBIT (Q1, 2021)

(4.3m)

Market capitalization (14-May-2021)

31.0m

Closing stock price (14-May-2021)

1.4

Cash (31-Mar-2021)

19.3m
Hoth Therapeutics's current market capitalization is $31 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

1.2m

R&D expense

586.8k785.3k2.0m2.3m

Operating expense total

1.9m785.3k2.0m2.3m

EBIT

(1.9m)(2.5m)(7.7m)(7.3m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

R&D expense

134.8k388.9k490.3k647.2k927.7k1.5m

Operating expense total

134.8k388.9k490.3k647.2k927.7k1.5m

EBIT

(829.4k)(1.3m)(1.7m)(1.8m)(2.5m)(4.3m)

Interest expense

4.4k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.2m282.6k1.7m2.6m

Prepaid Expenses

12.4k110.1k89.8k

Current Assets

1.2m501.6k2.6m4.8m

PP&E

3.5k2.3k1.0k
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

1.5m737.7k5.2m4.1m3.2m4.3m4.9m19.3m

Prepaid Expenses

27.2k19.8k88.3k101.3k113.9k56.5k56.7k177.9k

Current Assets

1.5m757.5k5.3m4.2m4.1m4.9m7.0m20.5m

PP&E

2.9k2.6k2.0k1.7k1.4k738.0433.0
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.0m)(2.5m)(7.7m)(7.2m)

Depreciation and Amortization

188.01.2k1.2k1.0k

Accounts Payable

47.9k94.4k267.4k(152.0k)

Cash From Operating Activities

(465.2k)(2.1m)(4.9m)(6.1m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(1.7m)(1.9m)(829.4k)(2.1m)(3.8m)(1.8m)(4.3m)(4.3m)

Depreciation and Amortization

916.0302.0608.0916.0305.0610.0

Accounts Payable

1.5k(22.2k)(71.7k)65.0k(117.0k)113.7k(104.5k)453.9k

Cash From Operating Activities

(240.3k)(1.6m)(764.0k)(1.8m)(3.4m)(1.6m)(4.0m)(2.7m)
Show all financial metrics

Hoth Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Hoth Therapeutics Online and Social Media Presence

Embed Graph

Hoth Therapeutics News and Updates

Thinking about buying stock in Hoth Therapeutics, Castor Maritime, Clover Health Investments, Naked Brand, or Virgin Galactic?

NEW YORK, April 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOTH, CTRM, CLOV, NAKD, and SPCE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm

NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the Company's method for...

Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

NEW YORK, March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also...

Hoth Therapeutics Retains RedChip to Increase Investor Awareness

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts. RedChip is the leader in investor relations, financial media, and research...

Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline

NEW YORK, Feb. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and support care indications. Drug Pipeline Highlights:...

Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication

NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the...
Show more

Hoth Therapeutics Blogs

HOTH THERAPEUTICS, INC. TO PRESENT AT THE THINKEQUITY CONFERENCE

NEW YORK, April 30, 2019 /PRNewswire/ — Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today annou…

Hoth Therapeutics Frequently Asked Questions

  • How many employees does Hoth Therapeutics have?

    Hoth Therapeutics has 2 employees.

  • Who are Hoth Therapeutics competitors?

    Competitors of Hoth Therapeutics include Alexion Pharmaceuticals, KiOmed Pharma and Veloxis Pharmaceuticals.

  • Where is Hoth Therapeutics headquarters?

    Hoth Therapeutics headquarters is located at 1 Rockefeller Plaza, 10th Floor, New York.

  • Where are Hoth Therapeutics offices?

    Hoth Therapeutics has an office in New York.

  • How many offices does Hoth Therapeutics have?

    Hoth Therapeutics has 1 office.